Bifogade filer
PDF
The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven endoscopic core biopsy instrument, announces that clinical partner UC Davis Health has published an article on its website sharing positive experiences from the first clinical cases with EndoDrill® GI in the USA. Among other things, it is mentioned that EndoDrill[®] GI enables more accurate cancer diagnoses leading to improved treatment for patients, which can contribute to better patient outcomes.
At the end of January, as previously communicated, the first clinical cases with EndoDrill[®] GI were performed in the US by Dr. Antonio Mendoza Ladd (Medical Director of Gastrointestinal Endoscopy) at UC Davis Health, Sacramento. Now, the hospital in California has written an article summarizing the results from the first three patient cases. One case concerned sampling of submucous tumor in the stomach (GIST) and in two cases sampling was done in the pancreas. It was the first time ever that EndoDrill[®] GI was used for sampling of pancreatic tumors. The article describes the advantages of electric-driven EndoDrill[®] GI compared to today's standard of care, i.e. manually stabbing needle instruments.
Dr. Antonio Mendoza Ladd's first clinical experience with the EndoDrill[®] GI is overwhelmingly positive, as illustrated by several quotes:
"These initial biopsies obtained with this innovative technology provided us with tissue cores that surpassed the typical ones collected with regular needles… "With this novel procedure, we were able to easily get a higher-quality core sample on the first pass of the needle, allowing us to provide extra tissue to pathologists that can be used to improve the diagnostic yield of the sample"…"We are excited to offer our patients this novel endoscopic biopsy procedure that will allow us to reach more accurate diagnoses and, therefore, offer better treatment that could result in improved outcomes."
Link to the article:
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill[®], a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill[®] instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill[®] GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill[®] is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill[®] system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.